Evidence map›Paper›PMID 40727116›Full record

ArticleJournal of medical cases2025

Secondary Central Nervous System Lymphoma Involving Meninges: A Rare Case Report and a Comprehensive Review of Peripheral T-Cell Lymphoma, Not Otherwise Specified.

Mrudula Thiriveedi, Muralidhar Idamakanti, Siddharth Patel, Rafik ElBeblawy, Sujatha Baddam, Bala Nimmana, Virginia Dailey, Rishi Patel

Abstract readCase Reports
In one paragraph

Article in Journal of medical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mrudula ThiriveediDepartment of Internal Medicine, Decatur Morgan Hospital, Decatur, AL 35601, USA.
Muralidhar IdamakantiAdult Inpatient Medical Services (AIMS), Presbyterian Healthcare Services (PHS), Albuquerque, NM 87106, USA.ORCID https://orcid.org/0009-0004-3599-3003
Siddharth PatelDepartment of Internal Medicine, Decatur Morgan Hospital, Decatur, AL 35601, USA.
Rafik ElBeblawyDepartment of Internal Medicine, Decatur Morgan Hospital, Decatur, AL 35601, USA.
Sujatha BaddamDepartment of Internal Medicine, Huntsville Hospital, Huntsville, AL 35801, USA.
Bala NimmanaDepartment of Internal Medicine, Huntsville Hospital, Huntsville, AL 35801, USA.
Virginia DaileyDepartment of Pathology, Decatur Morgan Hospital, Decatur, AL 35601, USA.
Rishi PatelDepartment of Hematology Oncology, Decatur Morgan Hospital, Decatur, AL 35601, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL) that arises from mature T or natural killer (NK) cells, accounting for about 5% of all NHL cases. While PTCL-NOS typically involves lymph nodes, extranodal sites such as the skin, gastrointestinal tract, liver, and lungs can also be affected. Central nervous system (CNS) involvement is extremely rare, especially at the time of initial presentation. When it does occur, the brain is most commonly affected, followed by the spinal cord and meninges. We present a rare case of PTCL-NOS with secondary CNS lymphoma involving the meninges at initial diagnosis. Our patient is a 75-year-old male with multiple comorbidities who presented with several weeks of intermittent headaches. Imaging showed multiple extra-axial brain lesions with infiltration into extracranial soft tissues, epidural space, meninges, and brain parenchyma. A subsequent lymph node biopsy confirmed PTCL-NOS. He was started on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with plans for high-dose methotrexate. Thereafter, the patient was readmitted several times due to various complications and expired approximately 2.5 months after diagnosis. We conclude that secondary CNS involvement in PTCL-NOS is very rare and has a poor prognosis, with a median survival after CNS diagnosis of about 1.1 months. Early diagnosis and tailored treatment strategies, including CNS-penetrating agents, are essential. Continued research is needed to better understand and improve outcomes for this aggressive disease.

Indexed as

LymphomaMethotrexateNon-Hodgkin lymphomasPeripheral T-cell lymphomaPeripheral T-cell lymphoma, not otherwise specifiedPrimary CNS lymphomaSecondary CNS lymphoma

Identifiers

PMID40727116
PMCPMC12292011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.